BWAY
Live News • Jun 30
BrainsWay Reports 83% PTSD Symptom Reduction in Largest Real-World Deep TMS Study BrainsWay reported real-world data from the largest study of its Deep TMS treatment in patients with both PTSD and major depressive disorder, with about 83.5% of patients achieving at least a 50% reduction in PTSD symptoms and an average reduction of 52%.
The results suggest BrainsWay’s Deep TMS could address a complex patient group with comorbid conditions, which may be important for discussions with clinicians and payers considering non-drug treatment options.
BrainsWay’s stock last traded at ₪46.00, with a year-to-date return of 49.9%.
The main investor read-through is that clinically relevant outcomes in a hard-to-treat population may support broader clinical adoption and reimbursement discussions for BrainsWay’s Deep TMS platform. However, the commercial impact will depend on how quickly these data translate into treatment protocols and coverage decisions. Announcement • Jun 29
Brainsway Ltd. Presents Positive Data From Largest Real-World Study Of Deep TMS In Patients With Comorbid PTSD And Major Depressive Disorder Brainsway Ltd. announced the presentation of positive new real-world data demonstrating significant improvements in patients with comorbid post-traumatic stress disorder (PTSD) and Major Depressive Disorder (MDD) treated with Deep Transcranial Magnetic Stimulation (Deep TMS). This real-world data collection study evaluated the efficacy of Deep TMS as a tool to improve both PTSD and MDD symptoms in patients with comorbid disease. All 462 patients in the retrospective study, from 11 clinical sites, were diagnosed with both MDD and PTSD, received at least 20 Deep TMS treatment sessions using BrainsWay's H1 or H7 coils. Outcomes included changes in the PTSD Checklist for DSM-5 (PCL-5) and the Patient Health Questionnaire-9 (PHQ-9) before and after treatment. Of these patients, 83.5% experienced a response (a reduction in PTSD symptoms of 50%), with an average 52% reduction in PCL-5 scores. Patients also experienced substantial improvements in depression symptoms, including a 66.6% response rate (a reduction in depression symptoms of 50%), a 27.3% remission rate, and an average 50% reduction in PHQ-9 scores. Deep TMS is not currently cleared by the FDA for the treatment of PTSD and/or comorbid PTSD and MDD, and the preliminary findings from the real-world study remain subject to peer review analysis. BrainsWay continues to lead the field with its proprietary H-coil technology, robust clinical research, and ongoing collaboration with providers and policymakers to expand access to care and improve the lives of patients. Announcement • Jun 10
BrainsWay Presents First SWIFT Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting BrainsWay presented new prospective 12-month durability data demonstrating sustained clinical benefits following accelerated Deep Transcranial Magnetic Stimulation (Deep TMS) for Major Depressive Disorder (MDD). The findings were recently presented in a poster by Colleen Hanlon, PhD, Vice President of Medical Affairs for BrainsWay, at the 14 Annual Clinical TMS Society (CTMSS) Meeting which was held on June 4-6, 2026. The data represented outcomes from the first multisite, randomized, controlled trial evaluating the long-term outcomes of BrainsWay's SWIFT protocol, an FDA-cleared Deep TMS protocol which reduces the number of clinic visits in the acute phase by 70% in comparison to the traditional standard protocol. Over 80% of patients treated with the SWIFT protocol were in remission through the 12-month follow-up period, based on clinician-rated assessments. Among those that received the SWIFT protocol, the percent of patients with severe functional impairment decreased dramatically from 85% at baseline to 0% at 12 months, supporting the real-world impact of Deep TMS on work performance, social engagement, relationships, and overall well-being. Less than 25% of patients had a change in their prescribed medication or another course of TMS within the 12-month period to treat their depression. The durable remission, response, and quality of life changes with the SWIFT protocol were also present in the group that received standard once a day Deep TMS, highlighting the overall durability of the Deep TMS technology for treating depression. The new prospective study followed patients that had enrolled in BrainsWay's original FDA pivotal non-inferiority trial which had compared the SWIFT accelerated protocol (5 sessions per day for 6 half days, followed by 4 weekly follow up visits) with BrainsWay's standard Deep TMS protocol (1 daily session, 5 days per week over 4 weeks, followed by 2 daily sessions per week for 2 weeks). Of the 89 patients that had completed the original pivotal trial (Phase 1), 73% (65 patients) consented to participate in this new one-year durability trial (Phase 2). These participants were evaluated at 3, 6, 9, and 12 months using clinician-rated and patient-reported outcome measures. The durability study outcomes build upon the previously reported pivotal trial results that supported FDA clearance of the BrainsWay SWIFT protocol for the treatment of Major Depressive Disorder in September 2025. Together, the data demonstrates both rapid antidepressant effects and sustained long-term outcomes, without the need for neuronavigation equipment. 
